AstraZeneca’s data add another landmark on the road to correlates of protection for COVID-19: Data Byte

Phase III data from a third COVID-19 vaccine, AstraZeneca’s AZD1222, shed more light on the neutralization titers needed to confer protection and have implications for other vaccines packaged in viral vectors. 

AstraZeneca plc (LSE:AZN; NASDAQ:AZN) and the University of Oxford announced Monday that their simian adenovirus vector-based vaccine AZD1222 produced 70% efficacy across two Phase III trials at an interim analysis. One of the trials was more positive than the other, however, at 90% efficacy vs 62%. ...